Open AccessEfficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
Author(s) -
William D. Chey,
Anthony Lembo,
Yang Yang,
David P. Rosenbaum
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000001056
Subject(s) - medicine , irritable bowel syndrome , placebo , constipation , discontinuation , diarrhea , abdominal pain , adverse effect , gastroenterology , clinical endpoint , defecation , randomized controlled trial , alternative medicine , pathology
Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).